Mizuho Cuts Chemours (NYSE:CC) Price Target to $21.00

Chemours (NYSE:CC) had its target price cut by investment analysts at Mizuho from $22.00 to $21.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has a “neutral” rating on the specialty chemicals company’s stock. Mizuho’s price objective suggests a potential upside of 14.19% from the stock’s current price.

Other equities research analysts also recently issued research reports about the company. Morgan Stanley lowered their price target on Chemours from $30.00 to $25.00 and set an “equal weight” rating for the company in a research report on Tuesday, November 5th. Royal Bank of Canada reissued an “outperform” rating and set a $25.00 price target on shares of Chemours in a research report on Thursday, December 12th. Barclays increased their price objective on shares of Chemours from $21.00 to $23.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. The Goldman Sachs Group cut their target price on Chemours from $24.00 to $21.00 and set a “neutral” rating on the stock in a research report on Tuesday. Finally, BMO Capital Markets raised their price objective on shares of Chemours from $30.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, October 7th. Five research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Chemours has an average rating of “Hold” and an average target price of $24.13.

Chemours Trading Up 8.6 %

NYSE:CC traded up $1.46 during mid-day trading on Tuesday, reaching $18.39. The company’s stock had a trading volume of 703,510 shares, compared to its average volume of 1,154,895. The company has a debt-to-equity ratio of 6.05, a current ratio of 1.73 and a quick ratio of 0.92. The stock has a market cap of $2.75 billion, a P/E ratio of 36.78 and a beta of 1.83. The company’s fifty day simple moving average is $19.28 and its two-hundred day simple moving average is $20.00. Chemours has a twelve month low of $15.10 and a twelve month high of $32.48.

Chemours (NYSE:CC) last released its earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.32 by $0.08. The firm had revenue of $1.50 billion during the quarter, compared to the consensus estimate of $1.44 billion. Chemours had a net margin of 1.34% and a return on equity of 29.48%. Chemours’s revenue was up .9% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.64 earnings per share. On average, equities analysts predict that Chemours will post 1.35 EPS for the current year.

Insider Buying and Selling at Chemours

In related news, SVP Alvenia Scarborough sold 7,500 shares of the stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $20.64, for a total value of $154,800.00. Following the completion of the transaction, the senior vice president now directly owns 16,645 shares of the company’s stock, valued at $343,552.80. This represents a 31.06 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.47% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Matrix Trust Co acquired a new stake in shares of Chemours in the 3rd quarter worth approximately $25,000. Blue Trust Inc. lifted its position in Chemours by 166.9% in the third quarter. Blue Trust Inc. now owns 1,169 shares of the specialty chemicals company’s stock worth $26,000 after purchasing an additional 731 shares during the period. GAMMA Investing LLC boosted its stake in Chemours by 99.7% during the 4th quarter. GAMMA Investing LLC now owns 1,532 shares of the specialty chemicals company’s stock valued at $26,000 after purchasing an additional 765 shares in the last quarter. Truvestments Capital LLC acquired a new position in shares of Chemours during the 3rd quarter valued at $35,000. Finally, Brooklyn Investment Group bought a new stake in shares of Chemours in the 3rd quarter worth $37,000. Institutional investors and hedge funds own 76.26% of the company’s stock.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.